Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Declines By 43.2%

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 8,400 shares, a decline of 43.2% from the October 31st total of 14,800 shares. Based on an average daily trading volume, of 20,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.7% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a report on Friday, November 22nd.

Xenetic Biosciences Stock Up 0.2 %

XBIO stock opened at $4.12 on Thursday. The firm has a market cap of $6.34 million, a PE ratio of -1.55 and a beta of 2.25. The business has a 50 day moving average of $3.92 and a 200-day moving average of $3.92. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.75 million. On average, research analysts expect that Xenetic Biosciences will post -1.01 earnings per share for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.